Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 27 min read

  1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12:1580–90. 10.1111/jth.1269825302663
  2. Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245–8. 10.1001/archinte.162.11.124512038942
  3. Roberts LN, Porter G, Barker RD, Yorke R, Bonner L, Patel RK, Arya R. Comprehensive VTE prevention program incorporating mandatory risk assessment reduces the incidence of hospital-associated thrombosis. Chest 2013; 144:1276–81. 10.1378/chest.13-026723681495
  4. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83:14–9.10669147
  5. Hunt BJ. Preventing hospital associated venous thromboembolism. BMJ 2019;365:l4239. 10.1136/bmj.l423931227478
  6. Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ) 2001;(43):i–x, 1–668. https://pubmed.ncbi.nlm.nih.gov/11510252/11510252
  7. Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf 2013;22:809–15. 10.1136/bmjqs-2012-001748
  8. National Institute for Health and Care Excellence. Venous Thromboembolism in Over 16s: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis or Pulmonary Embolism (NG89). London, UK: National Institute for Health and Care Excellence; 2018. URL: www.nice.org.uk/guidance/ng89 (accessed 22 July 2022).
  9. Huang W, Anderson FA, Spencer FA, Gallus A, Goldberg RJ. Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review. J Thromb Thrombolysis 2013;35:67–80. 10.1007/s11239-012-0780-022826096
  10. Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. Thromb Haemost 2017;117:801–8. 10.1160/TH16-08-063128150851
  11. Le P, Martinez KA, Pappas MA, Rothberg MB. A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients. J Thromb Haemost 2017;15:1132–41. 10.1111/jth.1368728371250
  12. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913–30. 10.1046/j.0007-1323.2001.01800.x11442521
  13. Australian Commission on Safety and Quality in Healthcare. Venous Thromboembolism Prevention - Clinical Care Standard. 2020. URL: www.safetyandquality.gov.au/sites/default/files/2020-01/venous_thromboembolism_prevention_clinical_care_standard_-_jan_2020_2.pdf (accessed 20 August 2021).
  14. Schunemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018;2:3198–225. 10.1182/bloodadvances.201802295430482763
  15. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J Thromb Haemost 2010;8:2450–7. 10.1111/j.1538-7836.2010.04044.x20738765
  16. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e195S–226S. 10.1378/chest.11-229622315261
  17. Pandor A, Tonkins M, Goodacre S, Sworn K, Clowes M, Griffin XL, et al. Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review. BMJ Open 2021;11:e045672. 10.1136/bmjopen-2020-045672
  18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9, W64w64. 10.7326/0003-4819-151-4-200908180-0013519622511
  19. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med 2019;170:W1–33. 10.7326/m18-137730596876
  20. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al.; PROBAST Group. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med 2019;170:51–8. 10.7326/m18-137630596875
  21. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. York: Centre for Reviews and Dissemination; 2009.
  22. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV. Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019) [Internet]. Cochrane; 2019.
  23. Hosmer DW, Lemeshow S. Applied Logistic Regression (2nd edn). New York, NY: John Wiley & Sons; 2000.
  24. Abdel-Razeq HN, Hijjawi SB, Jallad SG, Ababneh BA. Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience. J Thromb Thrombolysis 2010; 30:286–93. 10.1007/s11239-010-0445-920127272
  25. Autar R. The management of deep vein thrombosis: the Autar DVT risk assessment scale re-visited. J Orthop Nurs 2003;7:114–24.
  26. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010;251:344–50. 10.1097/SLA.0b013e3181b7fca619779324
  27. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY, Cohen ME. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg 2013;217:833–42.e1. https://doi.org/https://doi.org/10.1016/j.jamcollsurg.2013.07.38524055383
  28. Blondon M, Righini M, Nendaz M, Glauser F, Robert-Ebadi H, Prandoni P, et al. External validation of the simplified Geneva risk assessment model for hospital-associated venous thromboembolism in the Padua cohort. J Thromb Haemost 2019;18(3):676–80. https://doi.org/doi: 10.1111/jth.1468831782886
  29. Blondon M, Limacher A, Righini M, Aujesky D, Mean M. Adequacy of hospital thromboprophylaxis and risk assessment models in the SWITCO65+ cohort. Res Pract Thromb Haemost 2019;3:760. 10.1002/rth2.12229
  30. Blondon M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH, et al. Comparative performance of clinical risk assessment models for hospital-acquired venous thromboembolism in medical patients. Thromb Haemost 2018;118:82–9. https://doi.org/https://dx.doi.org/10.1160/TH17-06-040329304528
  31. Bo H, Li Y, Liu G, Ma Y, Li Z, Cao J, et al. Assessing the risk for development of deep vein thrombosis among Chinese patients using the 2010 Caprini risk assessment model: a prospective multicenter study. J Atheroscler Thromb 2020;27:801–8. https://doi.org/https://dx.doi.org/10.5551/jat.5135931852858
  32. Chen X, Pan L, Deng H, Zhang J, Tong X, Huang H, et al. Risk assessment in Chinese hospitalized patients comparing the Padua and Caprini Scoring algorithms. Clin Appl Thromb Hemost 2018;24(9_suppl):127S–135S. 10.1177/107602961879746530198321
  33. Cobben MRR, Nemeth B, Lijfering WM, Cannegieter SC. Validation of risk assessment models for venous thrombosis in hospitalized medical patients. Res Pract Thromb Haemost 2019;3:217–25. 10.1002/rth2.12181
  34. de Bastos M, Barreto SM, Caiafa JS, Boguchi T, Silva JLP, Rezende SM. Derivation of a risk assessment model for hospital-acquired venous thrombosis: the NAVAL score. J Thromb Thrombolysis 2016;41:628–35. 10.1007/s11239-015-1277-426446587
  35. Dornbos DL, Shah V, Priddy B, Schunemann V, Nimjee S, Powers C. Predicting venous thromboembolic complications following neurological surgery procedures. J Neurosurg 2018;128:55. 10.3171/2018.4.JNS.AANS2018abstracts
  36. Elias P, Khanna R, Dudley A, Davies J, Jacolbia R, McArthur K, Auerbach AD. Automating venous thromboembolism risk calculation using electronic health record data upon hospital admission: The automated Padua prediction score. J Hosp Med 2017;12:231–7. 10.12788/jhm.271428411291
  37. Frankel JK, Belanger M, Tortora J, McLaughlin T, Staff I, Wagner J. Caprini score predicts venous thromboembolic events in patients undergoing robotic assisted prostatectomy. J Urol 2017;197:e635.
  38. Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA. Assessing the Caprini score for risk assessment of venous thromboembolism in hospitalized medical patients results presented at: The Society of Hospital Medicine Annual Meeting, March 26, 2014, Las Vegas, Nevada. Am J Med 2016;129:528–35. 10.1016/j.amjmed.2015.10.02726551977
  39. Greene MT, Spyropoulos AC, Chopra V, Grant PJ, Kaatz S, Bernstein SJ, et al. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med 2016;129:1001.e91001–1001.e18. 10.1016/j.amjmed.2016.03.031
  40. Hachey KJ, Hewes PD, Porter LP, Ridyard DG, Rosenkranz P, McAneny D, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg 2016;151:37–44.e1. 10.1016/j.jtcvs.2015.08.03926386868
  41. Hegsted D, Gritsiouk Y, Schlesinger P, Gardiner S, Dean Gubler K. Utility of the risk assessment profile for risk stratification of venous thrombotic events for trauma patients. Am J Surg 2013;205:517–20. 10.1016/j.amjsurg.2013.01.02223592157
  42. Hewes PD, Hachey KJ, Zhang XW, Tripodis Y, Rosenkranz P, Ebright MI, et al. Evaluation of the Caprini Model for venothromboembolism in esophagectomy patients. Ann Thorac Surg 2015;100:2072–8. 10.1016/j.athoracsur.2015.05.09826279363
  43. Ho KM, Rao S, Rittenhouse KJ, Rogers FB. Use of the Trauma Embolic Scoring System (TESS) to predict symptomatic deep vein thrombosis and fatal and non-fatal pulmonary embolism in severely injured patients. Anaesth Intensive Care 2014;42:709–14. 10.1177/0310057x140420060525342402
  44. Hu Y, Li X, Zhou H, Lin P, Zhang J, Huang D, et al. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study. Interact Cardiovasc Thorac Surg 2020;31:454–60. 10.1093/icvts/ivaa13732910201
  45. Krasnow R, Preston M, Chung B, Kibel A, Chang S. Validation of venous thromboembolism risk assessment score in major urologic cancer surgery: a population based study. J Urol 2017;197:e1126.
  46. Liu L-P, Zheng H-G, Wang DZ, Wang Y-L, Hussain M, Sun H-X, et al. Risk assessment of deep-vein thrombosis after acute stroke: a prospective study using clinical factors. CNS Neurosci Ther 2014;20:403–10. 10.1111/cns.1222724612485
  47. Liu X, Liu C, Chen X, Wu W, Lu G. Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study. Interact Cardiovasc Thorac Surg 2016;23:538–43. 10.1093/icvts/ivw15827297558
  48. Lobastov K, Barinov V, Schastlivtsev I, Laberko L, Rodoman G, Boyarintsev V. Validation of the Caprini risk assessment model for venous thromboembolism in high-risk surgical patients in the background of standard prophylaxis. J Vasc Surg Venous Lymphat Disord 2016;4:153–60. 10.1016/j.jvsv.2015.09.00426993860
  49. Mahan CE, Liu Y, Turpie AG, Vu JT, Heddle N, Cook RJ, et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 2014;112:692–9. 10.1160/TH14-03-023924990708
  50. Mlaver E, Lynde GC, Gallion C, Sweeney JF, Sharma J. Development of a novel preoperative venous thromboembolism risk assessment model. Am Surg 2020;86:1098–105. 10.1177/000313482094355632967431
  51. Moumneh T, Riou J, Douillet D, Henni S, Mottier D, Tritschler T, et al. Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: a cohort study. J Thromb Haemost 2020;18:1398–407. 10.1111/jth.1479632168402
  52. Nafee T, Gibson CM, Travis R, Yee MK, Kerneis M, Chi G, et al. Machine learning to predict venous thrombosis in acutely ill medical patients. Res Pract Thromb Haemost 2020;4:230–7. 10.1002/rth2.1229232110753
  53. Nendaz M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH, et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost 2014;111:531–8. 10.1160/TH13-05-042724226257
  54. Pannucci CJ, Laird S, Dimick JB, Campbell DA, Henke PK. A validated risk model to predict 90-day VTE events in postsurgical patients. Chest 2014;145:567–73. 10.1378/chest.13-155324091567
  55. Pannucci CJ, Osborne NH, Wahl WL. Creation and validation of a simple venous thromboembolism risk scoring tool for thermally injured patients: analysis of the National Burn Repository. J Burn Care Res 2012;33:20–5. 10.1097/BCR.0b013e318234d8b521979848
  56. Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Hematol 2017;92:501–7. https://doi.org/https://dx.doi.org/10.1002/ajh.2470028240823
  57. Rogers FB, Shackford SR, Horst MA, Miller JA, Wu D, Bradburn E, et al. Determining venous thromboembolic risk assessment for patients with trauma: the Trauma Embolic Scoring System. J Trauma Acute Care Surg 2012;73:511–5.23019680
  58. Rogers SO Jr, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007;204:1211–21.17544079
  59. Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014;3:e001152. 10.1161/JAHA.114.00115225404191
  60. Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med 2011;6:202–9. 10.1002/jhm.88821480491
  61. Shaikh M-A, Jeong HS, Mastro A, Davis K, Lysikowski J, Kenkel JM. Analysis of the American Society of Anesthesiologists Physical Status Classification System and Caprini Risk Assessment Model in predicting venous thromboembolic outcomes in plastic surgery patients. Aesthet Surg J 2016; 36:497–505. 10.1093/asj/sjv19826673574
  62. Shang M-M, Yan R, Wang X-L, Gong W-P, Guo Z-Q. Comparison of 2013 and 2009 versions of Caprini risk assessment models for predicting VTE in Chinese cancer patients: a retrospective study. J Thromb Thrombolysis 2020;50:446–51. 10.1007/s11239-020-02038-231975322
  63. Shen C, Ge B, Liu X, Chen H, Qin Y, Shen H. Predicting the occurrence of venous thromboembolism: construction and verification of risk warning model. BMC Cardiovasc Disord 2020;20:249. 10.1186/s12872-020-01519-932460701
  64. Tachino J, Yamamoto K, Shimizu K, Shintani A, Kimura A, Ogura H, Shimazu T. Quick risk assessment profile (qRAP) is a prediction model for post-traumatic venous thromboembolism. Injury 2019;50:1540–4. 10.1016/j.injury.2019.06.02031248583
  65. Tian B, Li H, Cui S, Song C, Li T, Hu B. A novel risk assessment model for venous thromboembolism after major thoracic surgery: a Chinese single-center study. J Thorac Dis 2019;11:1903–10. 10.21037/jtd.2019.05.1131285883
  66. Vardi M, Ghanem-Zoubi NO, Zidan R, Yurin V, Bitterman H. Venous thromboembolism and the utility of the Padua prediction score in patients with sepsis admitted to internal medicine departments. J Thromb Haemost 2013;11:467–73. 10.1111/jth.1210823279085
  67. Vaziri S, Wilson J, Abbatematteo J, Kubilis P, Chakraborty S, Kshitij K, et al. Predictive performance of the American College of Surgeons universal risk calculator in neurosurgical patients. J Neurosurg 2018;128:942–7. 10.3171/2016.11.JNS16137728452615
  68. Vincentelli GM, Timpone S, Murdolo G, Fusco Moffa I, L’Angiocola PD, Borgognoni F, et al. A new risk assessment model for the stratification of the thromboembolism risk in medical patients: the TEVere Score. Minerva medica 2018;109:436–42. 10.23736/S0026-4806.18.05689-629856190
  69. Wang X, Yang Y-Q, Liu S-H, Hong X-Y, Sun X-F, Shi J-H. Comparing different venous thromboembolism risk assessment machine learning models in Chinese patients. J Eval Clin Pract 2020;26:26–34. 10.1111/jep.1332431840330
  70. Winoker JS, Paulucci DJ, Anastos H, Waingankar N, Abaza R, Eun DD, et al. Predicting complications following robot-assisted partial nephrectomy with the ACS NSQIP universal surgical risk calculator. J Urol 2017;198:803–9. 10.1016/j.juro.2017.04.02128400189
  71. Woller SC, Stevens SM, Jones JP, Lloyd JF, Evans RS, Aston VT, Elliott CG. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med 2011;124:947–954.e2. 10.1016/j.amjmed.2011.06.00421962315
  72. Zhou H, Hu Y, Li X, Wang L, Wang M, Xiao J, Yi Q. Assessment of the risk of venous thromboembolism in medical inpatients using the Padua prediction score and Caprini risk assessment model. J Atheroscler Thromb 2018;25:1091–104. 10.5551/jat.4365329540637
  73. Zhou H, Wang L, Wu X, Tang Y, Yang J, Wang B, et al. Validation of a venous thromboembolism risk assessment model in hospitalized Chinese patients: a case–control study. J Atheroscler Thromb 2014;21:261–72. 10.5551/jat.2089124304962
  74. Pandor A, Horner D, Davis S, Goodacre S, Stevens JW, Clowes M, et al. Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technol Assess 2019;23:1–190. 10.3310/hta23630
  75. Shalhoub J, Lawton R, Hudson J, Baker C, Bradbury A, Dhillon K, et al.; GAPS trial investigators. Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial. BMJ 2020;369:m1309. 10.1136/bmj.m130932404430
  76. Gee E. The National VTE Exemplar Centres Network response to implementation of updated NICE guidance: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89). Br J Haematol 2019;186:792–3. 10.1111/bjh.1601031168834
  77. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Care Excellence; 2013.
  78. Curtis X, Burns X. Unit Costs of Health and Social Care. UK: Canterbury; 2019.
  79. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, et al.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202–4. 10.1111/j.1538-7836.2009.03678.x19878532
  80. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–4. 10.1111/j.1538-7836.2005.01204.x15842354
  81. Fowler AJ, Abbott TEF, Prowle J, Pearse RM. Age of patients undergoing surgery. Br J Surg 2019;106:1012–8. 10.1002/bjs.1114831115918
  82. Hewitt J, Carter B, McCarthy K, Pearce L, Law J, Wilson FV, et al. Frailty predicts mortality in all emergency surgical admissions regardless of age. An observational study. Age Ageing 2019;48:388–94. 10.1093/ageing/afy21730778528
  83. Moore E, Munoz-Arroyo R, Schofield L, Radley A, Clark D, Isles C. Death within 1 year among emergency medical admissions to Scottish hospitals: incident cohort study. BMJ Open 2018;8:e021432. 10.1136/bmjopen-2017-021432
  84. Digital N. Summary Hospital-level Mortality Indicator (SHMI) – Deaths associated with hospitalisation, England, December 2018–November 2019. Journal 2020. URL: https://digital.nhs.uk/data-and-information/publications/statistical/shmi/2020-04/shmi-december-2018---november-2019 (accessed 9 April 2020).
  85. Clark D, Schofield L, Graham F, Isles C, Gott M, Jarlbaek L. Likelihood of death within one year among a National Cohort of Hospital Inpatients in Scotland. J Pain Symptom Manage 2016;52:E2–4. 10.1016/j.jpainsymman.2016.05.007
  86. National Institute for Health and Care Excellence. Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital. NICE Clinical Guidelines, No. 92 . London, UK: Royal College of Physicians, NICE; 2018.
  87. Lederle FA, Sacks JM, Fiore L, Landefeld CS, Steinberg N, Peters RW, et al. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 2006;119:54–9. 10.1016/j.amjmed.2005.03.049
  88. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, et al.; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874–9. 10.1161/01.CIR.0000138928.83266.2415289368
  89. Mahe I, Bergmann JF, d’Azemar P, Vaissie JJ, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomized double-blind study. Eur J Clin Pharmacol 2005;61:347–51. 10.1007/s00228-005-0944-315981008
  90. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793–800. 10.1056/NEJM19990909341110310477777
  91. Wade R, Sideris E, Paton F, Rice S, Palmer S, Fox D, et al. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technol Assess 2015;19:1–220. 10.3310/hta19980
  92. Shalhoub J, Lawton R, Hudson J, Baker C, Bradbury A, Dhillon K, et al. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT. Health Technol Assess 2020;24:1–80. 10.3310/hta24690
  93. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al.; IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011;139:69–79. 10.1378/chest.09-308120453069
  94. Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungstrom KG, et al. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. Vasa 1996;25:156–60.8659218
  95. Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N, Okamoto A. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J Obstet Gynaecol Res 2015;41:1440–8. 10.1111/jog.1274026111609
  96. Osman Y, Kamal M, Soliman S, Sheashaa H, Shokeir A, Shehab el-Dein AB. Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology 2007;69:647–51. 10.1016/j.urology.2006.12.01717445644
  97. Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res 2010;125:e65–70. 10.1016/j.thromres.2009.09.00919919878
  98. Song KY, Yoo HM, Kim EY, Kim JI, Yim HW, Jeon HM, Park CH. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial. Ann Surg Oncol 2014;21:4232–8. 10.1245/s10434-014-3893-125012265
  99. Jameson SS, Charman SC, Gregg PJ, Reed MR, van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. J Bone Joint Surg Br 2011;93:1465–70. 10.1302/0301-620X.93B11.2762222058295
  100. Jameson SS, Baker PN, Charman SC, Deehan DJ, Reed MR, Gregg PJ, Van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data. J Bone Joint Surg Br 2012;94:914–8. 10.1302/0301-620X.94B7.2912922733945
  101. Cushner F, Agnelli G, FitzGerald G, Warwick D. Complications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ) 2010;39:22–8.
  102. Pedersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice. Bone Joint J 2014;96-B:479–85. 10.1302/0301-620X.96B4.3320924692614
  103. Turpie AG, Haas S, Kreutz R, Mantovani LG, Pattanayak CW, Holberg G, et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost 2014;111:94–102. 10.1160/TH13-08-066624154549
  104. Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJ, et al. The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLOS ONE 2015;10:e0122520. 10.1371/journal.pone.012252025905638
  105. Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost 2017;117:1326–37. 10.1160/TH16-10-079328405675
  106. Nieto JA, Solano R, Ruiz-Ribo MD, Ruiz-Gimenez N, Prandoni P, Kearon C, Monreal M; RIETE Investigators. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010;8:1216–22. 10.1111/j.1538-7836.2010.03852.x20345727
  107. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010;152:578–89. 10.7326/0003-4819-152-9-201005040-0000820439576
  108. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 2017;49:1601792. 10.1183/13993003.01792-201628232411
  109. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al.; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257–64. 10.1056/NEJMoa03227415163775
  110. Hach-Wunderle V, Bauersachs R, Gerlach HE, Eberle S, Schellong S, Riess H, et al. Postthrombotic syndrome 3 years after deep venous thrombosis in the Thrombosis and Pulmonary Embolism in Out-patients (TULIPA) PLUS Registry. J Vasc Surg Venous Lymphat Disord 2013;1:5–12. 10.1016/j.jvsv.2012.07.00326993886
  111. van Dongen CJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005;3:939–42. 10.1111/j.1538-7836.2005.01333.x15869588
  112. Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry 2005;76:1534–8. 10.1136/jnnp.2004.05514516227546
  113. Monreal M, Agnelli G, Chuang LH, Cohen AT, Gumbs PD, Bauersachs R, et al. Deep vein t in Europe-health-related quality of life and mortality. Clin Appl Thromb Hemost 2019; 25:1076029619883946. 10.1177/107602961988394631840534
  114. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445–53. 10.1001/archinte.159.5.44510074952
  115. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 1996;26:127–39. 10.1159/0002171988738587
  116. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, et al.; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010;153:8–18. 10.7326/0003-4819-153-1-201007060-0000420621900
  117. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, et al.; THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614–21. 10.1067/mhj.2003.18912679756
  118. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al.; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325–9. 10.1136/bmj.38733.466748.7C16439370
  119. Goodacre S, Horspool K, Shephard N, Pollard D, Hunt BJ, Fuller G, et al. Selecting pregnant or postpartum women with suspected pulmonary embolism for diagnostic imaging: the DiPEP diagnostic study with decision-analysis modelling. Health Technol Assess 2018;22:1–230. 10.3310/hta22470
  120. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016;133:859–71. 10.1161/CIRCULATIONAHA.115.01652226826181
  121. Menakaya CU, Pennington N, Muthukumar N, Joel J, Ramirez Jimenez AJ, Shaw CJ, Mohsen A. The cost of outpatient venous thromboembolism prophylaxis following lower limb injuries. Bone Joint J 2013;95-B:673–7. 10.1302/0301-620X.95B5.3055523632680
  122. Sweetland S, Green J, Liu B, Berrington de Gonzalez A, Canonico M, Reeves G, Beral V. Million Women Study collaborators. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2009;339:b4583. 10.1136/bmj.b458319959589
  123. Luengo-Fernandez R, Gray AM, Bull L, Welch S, Cuthbertson F, Rothwell PM, et al.; Oxford Vascular Study. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology 2013;81:1588–95. 10.1212/WNL.0b013e3182a9f45f24107865
  124. Luengo-Fernandez R, Yiin GS, Gray AM, Rothwell PM. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke 2013;8:308–14. 10.1111/j.1747-4949.2012.00812.x22568484
  125. NHS Improvement. National Cost Collection: National Schedule of NHS costs – Year 2018-19 - NHS Trust and NHS Foundation. London, UK: NHS Improvement; 2021.
  126. Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59–74. 10.1046/j.1524-4733.2003.00204.x12535239
  127. Lubberts B, Paulino Pereira NR, Kabrhel C, Kuter DJ, DiGiovanni CW. What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis. Thromb Haemost 2016;116:417–31. 10.1160/TH16-02-015227362694
  128. Ghanima W, Wik HS, Tavoly M, Enden T, Jelsness-Jorgensen LP. Late consequences of venous thromboembolism: measuring quality of life after deep vein thrombosis and pulmonary embolism. Thromb Res 2018;164:170–6. 10.1016/j.thromres.2017.07.02528760416
  129. Utne KK, Dahm A, Wik HS, Jelsness-Jorgensen LP, Sandset PM, Ghanima W. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res 2018;163:6–11. 10.1016/j.thromres.2018.01.01329324334
  130. Chuang LH, Gumbs P, van Hout B, Agnelli G, Kroep S, Monreal M, et al. Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Qual Life Res 2019;28:2111–24. 10.1007/s11136-019-02175-z30949836
  131. Amin AP, Bachuwar A, Reid KJ, Chhatriwalla AK, Salisbury AC, Yeh RW, et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 2013; 61:2130–8. 10.1016/j.jacc.2013.02.04423541975
  132. Amin AP, Wang TY, McCoy L, Bach RG, Effron MB, Peterson ED, Cohen DJ. Impact of bleeding on quality of life in patients on DAPT: insights from TRANSLATE-ACS. J Am Coll Cardiol 2016;67:59–65. 10.1016/j.jacc.2015.10.03426764067
  133. Enden T, Wik HS, Kvam AK, Haig Y, Klow NE, Sandset PM. Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. BMJ Open 2013;3:e002984. 10.1136/bmjopen-2013-002984
  134. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997;4:49–56. 10.1136/jamia.1997.00400498988474
  135. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, Pepke-Zaba J. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 2008;32:1513–9. 10.1183/09031936.0006970818768576
  136. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001;111:130–9. 10.1016/s0002-9343(01)00793-811498067
  137. Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 2011;14:539–45. 10.1016/j.jval.2010.10.02921669378
  138. Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007;5:1438–43. 10.1111/j.1538-7836.2007.02571.x17425687
  139. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857–72. 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e9595616
  140. Hirst E, Irving A, Goodacre S. Patient and public involvement in emergency care research. Emerg Med J 2016;33:665–70. 10.1136/emermed-2016-20570027044949
  141. National Institute for Health and Care Excellence. COVID-19 Rapid Guideline [NG186]: Reducing the Risk of Venous Thromboembolism in Over 16s with COVID-19. 2020. URL: www.nice.org.uk/guidance/ng186 (accessed 22 July 2022).
  142. Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991;17(Suppl 3):304–12.1754886
  143. Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost 2006;4:915–6. 10.1111/j.1538-7836.2006.01818.x16634771
  144. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S–400S. 10.1378/chest.126.3_suppl.338S15383478
  145. Horner D, Goodacre S, Davis S, Burton N, Hunt BJ. Which is the best model to assess risk for venous thromboembolism in hospitalised patients? BMJ 2021;373:n1106. 10.1136/bmj.n110634045235
  146. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005;352:969–77. 10.1056/NEJMoa04153315758007
  147. Rosenberg DJ, Press A, Fishbein J, Lesser M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. Thromb Haemost 2016;116:530–6. 10.1160/TH16-01-000327307054
  148. Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, et al.; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011;140:706–14. 10.1378/chest.10-194421436241
  149. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al. IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936–45. 10.1378/chest.06-299317573514
  150. Roberts LN, Hunt B, Arya R, Briggs T. National Thrombosis Survey. URL: https://thrombosisuk.org/. 2021 (accessed 22 July 2022).
  151. Sharma A, Minh Duc NT, Luu Lam Thang T, Nam NH, Ng SJ, Abbas KS, et al. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J Gen Intern Med 2021;36:3179–87. 10.1007/s11606-021-06737-133886027
  152. Cobben M, Nemeth B, Lijfering W. Validation of risk assessment models for venous thrombosis in hospitalised medical inpatients. Res Pract Thromb Haemost 2019;3:217–25. 10.1002/rth2.12181
  153. Darzi AJ, Karam SG, Spencer FA, Spyropoulos AC, Mbuagbaw L, Woller SC, et al. Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. Blood Adv 2020;4:2557–66. 10.1182/bloodadvances.202000193732542391
  154. Wright FL, Green J, Canoy D, Cairns BJ, Balkwill A, Beral V, et al.; Million Women Study Collaborators. Vascular disease in women: comparison of diagnoses in hospital episode statistics and general practice records in England. BMC Med Res Methodol 2012;12:161. 10.1186/1471-2288-12-16123110714
  155. Abdul Sultan A, Tata LJ, Grainge MJ, West J. The incidence of first venous thromboembolism in and around pregnancy using linked primary and secondary care data: a population based cohort study from England and comparative meta-analysis. PLOS ONE 2013;8:e70310. 10.1371/journal.pone.007031023922975
  156. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000;49:591–6. 10.1046/j.1365-2125.2000.00199.x10848723
  157. Verma AA, Masoom H, Pou-Prom C, Shin S, Guerzhoy M, Fralick M, et al. Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients. Thromb Res 2021;209:51–8. 10.1016/j.thromres.2021.11.02034871982
  158. Sanfilippo KM, Wang TF, Gage BF, Liu W, Carson KR. Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. Thromb Res 2015;135:616–20. 10.1016/j.thromres.2015.01.01225613924
  159. Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. The validity of ICD codes coupled with imaging procedure codes for identifying acute venous thromboembolism using administrative data. Vasc Med 2015;20:364–8. 10.1177/1358863X1557383925834115
  160. Baumgartner C, Go AS, Fan D, Sung SH, Witt DM, Schmelzer JR, et al. Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study. Thromb Res 2020;189:112–8. 10.1016/j.thromres.2020.02.02332199174
  161. Pellathy T, Saul M, Clermont G, Dubrawski AW, Pinsky MR, Hravnak M. Accuracy of identifying hospital acquired venous thromboembolism by administrative coding: implications for big data and machine learning research. J Clin Monit Comput 2021;36(2):397–405. 10.1007/s10877-021-00664-633558981
  162. Sydes MR, Barbachano Y, Bowman L, Denwood T, Farmer A, Garfield-Birkbeck S, et al.; Data Enabled Trials Group Workshop Group members. Realising the full potential of data-enabled trials in the UK: a call for action. BMJ Open 2021;11:e043906. 10.1136/bmjopen-2020-043906
  163. Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006;21:722–7. 10.1111/j.1525-1497.2006.00458.x16808773
  164. Burles K, Innes G, Senior K, Lang E, McRae A. Limitations of pulmonary embolism ICD-10 codes in emergency department administrative data: let the buyer beware. BMC Med Res Methodol 2017;17:89. 10.1186/s12874-017-0361-128595574
  165. Powell GA, Bonnett LJ, Smith CT, Hughes DA, Williamson PR, Marson AG. Using routinely recorded data in a UK RCT: a comparison to standard prospective data collection methods. Trials 2021;22:429. 10.1186/s13063-021-05294-634225782
  166. Liaw ST, Chen HY, Maneze D, Taggart J, Dennis S, Vagholkar S, Bunker J. Health reform: is routinely collected electronic information fit for purpose? Emerg Med Australas 2012;24:57–63. 10.1111/j.1742-6723.2011.01486.x22313561
  167. Lowenstern A, Lippmann SJ, Brennan JM, Wang TY, Curtis LH, Feldman T, et al. Use of Medicare claims to identify adverse clinical outcomes after mitral valve repair. Circ Cardiovasc Interv 2019;12:e007451. 10.1161/CIRCINTERVENTIONS.118.00745131084236
  168. Macnair A, Love SB, Murray ML, Gilbert DC, Parmar MKB, Denwood T, et al. Accessing routinely collected health data to improve clinical trials: recent experience of access. Trials 2021;22:340. 10.1186/s13063-021-05295-533971933
  169. Jerome J. Thrombosis UK. https://thrombosisuk.org; 2021. URL: https://thrombosisuk.org (accessed 6 December 2021).
  170. Beck MJ, Haidet P, Todoric K, Lehman E, Sciamanna C. Reliability of a point-based VTE risk assessment tool in the hands of medical residents. J Hosp Med 2011;6:195–201. 10.1002/jhm.86021480490
  171. Vyas D. Variations in risk assessment models may contribute to the existing gap between venous thromboembolism prophylaxis guidelines and adherence. Springerplus 2012;1:60. 10.1186/2193-1801-1-6023450705
  172. Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, Cushman M, Gould MK, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood 2020;135:1788–810. 10.1182/blood.201900360332092132
  173. Zakai NA, Koh I, Wilkinson K, Roetker N, Sparks A, Repp A, et al. Risk assessing medical inpatients for hospital-acquired venous thrombosis: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study. Blood 2021;138:829.
  174. Nemeth B, Cannegieter SC. Venous thrombosis following lower-leg cast immobilization and knee arthroscopy: from a population-based approach to individualized therapy. Thromb Res 2019;174:62–75. 10.1016/j.thromres.2018.11.03030579148
  175. Nemeth B, Nelissen R, Arya R, Cannegieter S. Preventing VTE following total hip and knee arthroplasty: is prediction the future? J Thromb Haemost 2021;19:41–5. 10.1111/jth.1513233043553
  176. Nemeth B, van Adrichem R, Nelissen R, le Cessie S, Cannegieter SC. Individualized thromboprophylaxis in patients with lower-leg cast immobilization – a validation and subgroup analysis in the POT-CAST Trial. Thromb Haemost 2019;119:1508–16. 10.1055/s-0039-169341031352679
  177. NIHR. 21/588 Timing of Pharmacological Thromboprophylaxis in Traumatic Brain Injury Commissioning Brief. 2021. URL: www.nihr.ac.uk/documents/21588-timing-of-pharmacological-thromboprophylaxis-in-traumatic-brain-injury-commissioning-brief/29197 (accessed 6 December 2021).
  178. Goodacre S, Horspool K, Shephard N, Pollard D, Hunt BJ, Fuller G, et al. Selecting pregnant or postpartum women with suspected pulmonary embolism for diagnostic imaging: the DiPEP diagnostic study with decision-analysis modelling. Health Technol Assess 2018;22:1–230. 10.3310/hta22470
  179. Department of Health. National Schedule of Reference Costs – Year 2015–16 – NHS Trust and NHS Foundation Trusts. UK Department of Health and Social Care; 2016.
  180. Joint Formulary Committee. British National Formulary (online) [Drug Tariff]. London, UK. URL: www.medicinescomplete.com (accessed 24 January 2018).
  181. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Canterbury, UK: Personal Social Services Research Unit; 2017.
  182. National Clinical Guideline Centre – Acute and Chronic Conditions (UK). Venous Thromboembolism: Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital (NICE Clinical Guidelines, No. 92 .). London: Royal College of Physicians (UK); 2010. URL: www.ncbi.nlm.nih.gov/books/NBK116518/ (accessed 4 March 2018).
← ConclusionsAcknowledgements →

Attribution. Daniel Edward Horner; Sarah Davis; Abdullah Pandor; Helen Shulver; Steve Goodacre; Daniel Hind et al. (2024). Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis. National Institute for Health and Care Research. Copyright © 2024 Horner et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK602843. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support